Avaliação oftalmológica e laboratorial de coelhos hígidos tratados com os colírios dorzolamida a 2% e latanoprost a 0,005%

Abstract

The glaucoma is a progressive optical neuropathy generally associated to the increase of the intraocular pressure (IOP). The dorzolamide at 2% and the latanoprost at 0,005% are topical antiglaucoma drugs that cause significant reduction of the IOP. We decided to evaluate the local and systemic adverse effects of the dorzolamide at 2% and of the latanoprost at 0,005% in rabbits treated during 120 days. Eighteen rabbits were utilized, which were distributed in three groups (n=6). GI (latanoprost at 0,005%, SID); GII (dorzolamide at 2%, TID) and GIII (ultra-pure water, TID). Ophthalmological evaluation was carried out through daily clinical examination, Schirmer tear test and fluorescein stain. Also, the central corneal thickness (CCT) was measured as well as histopathologic evaluation of the eye and of annexes structures. For systemic evaluation was carried out blood count, biochemical analyses. At the end of the 120 days, of treatmentwere verified alterations in the eyelids and conjunctive and presence of eye secretion in respectively, 13,75% and 9,1% of the eyes of GI, 60% and 16,32% of the eyes of GII and, 0,62% and 0,48% of the eyes of GIII. The CCT test showed significant statistical difference only in the GII, where the CCT index was bigger in the end of the experiment. When facing the results, one can conclude that the treatment with the latanoprost at 0,005% promoted clinical alterations limited to the eyelids and the conjunctive of rabbits. In the other hand the dorzolamide at 2%, produced more intense alterations in the conjunctives and eyelids, lead to statistical significant increase in the CCT after 120 days of treatment